



April 9, 2018

## **Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines**

CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- [Genocea Biosciences, Inc.](#) (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research ([AACR 2018](#)), taking place April 14-18, 2018 in Chicago, IL.

### **Poster 15: "Neoantigen identification using the ATLAS T cell profiling platform highlights the need to empirically define neoantigens"**

Vaccines Session 1, Immunology Track

Sunday, April 15, 2018 from 1 pm to 5 pm CDT

[Link to abstract](#)

### **Poster 5718: "Ex vivo ATLAS-identification of neoantigens for personalized cancer immunotherapy in mouse melanoma"**

Neoantigens in Cancer Session, Immunology Track

Wednesday, April 18, 2018 from 8 am to 12 pm CDT

[Link to abstract](#)

### **About Genocea Biosciences, Inc.**

Genocea's mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit [www.genocea.com](http://www.genocea.com).

### **Contact:**

Jennifer LaVin

207-360-0473

[jennifer.lavin@genocea.com](mailto:jennifer.lavin@genocea.com)

 [Primary Logo](#)

Source: Genocea Biosciences, Inc.

News Provided by Acquire Media